An integrative functional genomics approach reveals EGLN1 as a novel therapeutic target in KRAS mutated lung adenocarcinoma

Francesca Reggiani; Elisabetta Sauta; Federica Torricelli; Eleonora Zanetti; Elena Tagliavini; Giacomo Santandrea; Giulia Gobbi; Giovanna Damia; Riccardo Bellazzi; Davide Ambrosetti; Alessia Ciarrocchi; Valentina Sancisi

ArticleOPEN ACCESS

An integrative functional genomics approach reveals EGLN1 as a novel therapeutic target in KRAS mutated lung adenocarcinoma

Reggiani F
Sauta E
Torricelli F
et al.

Molecular Cancer

DOI: 10.1186/s12943-021-01357-z

7Citations

12Readers

Author supplied keywords

CRISPR/Cas9 screening
EGLN1
HIF1A
KRAS
Lung cancer

Cite

CITATION STYLE

APA

Reggiani, F., Sauta, E., Torricelli, F., Zanetti, E., Tagliavini, E., Santandrea, G., … Sancisi, V. (2021, December 1). An integrative functional genomics approach reveals EGLN1 as a novel therapeutic target in KRAS mutated lung adenocarcinoma. Molecular Cancer. BioMed Central Ltd. https://doi.org/10.1186/s12943-021-01357-z

An integrative functional genomics approach reveals EGLN1 as a novel therapeutic target in KRAS mutated lung adenocarcinoma

Author supplied keywords

Cite

Register to see more suggestions